Technical details and progress of transcatheter hepatic arterial chemoembolization

doi:10.3877/cma.j.issn.2095-5782.2018.02.008

Abstract

Abstract:

Transcatheter hepatic arterial chemoembolization (TACE) is the most commonly used method in the treatment of hepatocellular carcinoma, but its technical details are controversial and difficult to standardize. Through literature review, we found that superselective catheterization was the basic requirement of TACE; Lipiodol has become an indispensable embolic material for its plastic embolization; Adding solid embolization materials could prolong the survival time; The role of chemotherapeutic drugs is questionable; And the concepts of "on-demand TACE" and "TACE resistance" are gradually accepted.

Key words: Transcatheter hepatic arterial chemoembolization, Primary hepatic tumor, Lipiodol, TACE refractory

Zhi Li, Caifang Ni. Technical details and progress of transcatheter hepatic arterial chemoembolization[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(02): 127-132.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2018.02.008

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/127

References 51

[1]	Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148(2): 397-401.
[2]	Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization[J]. Radiology, 1993, 188(1): 79-83.
[3]	Horikawa M, Miyayama S, Irie T, et al. Development of conventional transarterial chemoembolization for hepatocellular carcinomas in Japan: historical, strategic, and technical review[J]. AJR Am J Roentgenol, 2015, 205(4): 764-773.
[4]	Miyayama S, Matsui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization[J]. Cardiovasc Intervent Radiol, 2006, 29(1): 39-48.
[5]	Miyayama S, Yamashiro M, Okuda M, et al. Anastomosis between the hepatic artery and the extrahepatic collateral or between extrahepatic collaterals: observation on angiography[J]. J Med Imaging Radiat Oncol, 2009, 53(3): 271-282.
[6]	Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome[J]. J Vasc Interv Radiol, 2016, 27(9): 1269-1278.
[7]	Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? [J]. J Vasc Interv Radiol, 2013, 24(4): 509-517.
[8]	Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? [J]. Jpn J Radiol, 2012, 30(7): 560-566.
[9]	李照，朱继业.《原发性肝癌诊疗规范（2017年版）》解读[J].临床肝胆病杂志，2017，33(9): 1655-1657.
[10]	Idee JM, Guiu B. Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review[J]. Crit Rev Oncol Hematol, 2013, 88(3): 530-549.
[11]	Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium[J]. Cancer, 1990, 66(9): 1897-1903.
[12]	Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver[J]. Semin Intervent Radiol, 2008, 25(2): 77-85.
[13]	Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. An experimental investigation in several animal species[J]. Acta Radiol Suppl, 1996, 408: 1-25.
[14]	Goseki N, Nosaka T, Endo M, et al. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization[J]. Cancer, 1995, 76(5): 736-742.
[15]	Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3): 365-376.
[16]	Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264.
[17]	Li Z, Ni RF, Busireddy KK, et al. Cerebral lipiodol embolism following transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of two cases and literature review[J]. Chin Med J（Engl）, 2011, 124(24): 4355-4358.
[18]	Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis[J]. Cardiovasc Intervent Radiol, 1994, 17(2): 76-80.
[19]	Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment[J]. Eur J Pharm Sci, 2011, 44(1-2): 1-10.
[20]	de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study[J]. Radiology, 1995, 194(1): 165-170.
[21]	Park C, Choi SI, Kim H, et al. Distribution of Lipiodol in hepatocellular carcinoma[J]. Liver, 1990, 10(2): 72-78.
[22]	Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil[J]. Br J Cancer, 1996, 73(7): 877-881.
[23]	Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(3): 53-71.
[24]	Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma[J]. Aliment Pharmacol Ther 2012, 35(11): 1343-1350.
[25]	Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol, 2007, 30(1): 6-25.
[26]	Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency[J]. Cardiovasc Intervent Radiol, 2003, 26(2): 111-117.
[27]	Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol, 2010, 194(3): 830-837.
[28]	Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1): 3-11.
[29]	Jin B, Wang D, Lewandowski RJ, et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2011, 196(4): 919-928.
[30]	施昌盛，杨庆，李成. Embosphere微球联合弹簧圈栓塞治疗大咯血的疗效分析[J/CD].中华介入放射学电子杂志, 2017, 5(4):269-272.
[31]	Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents[J]. J Vasc Interv Radiol, 2005, 16(12): 1661-1666.
[32]	Illum L, Davis SS. The targeting of drugs parenterally by use of microspheres[J]. J Parenter Sci Technol, 1982, 36(6): 242-248.
[33]	Bastian P, Bartkowski R, Kohler H, et al. Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy[J]. Eur J Pharm Biopharm, 1998, 46(3): 243-254.
[34]	Lu W, Li Y, He X, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors[J]. Hepatogastroenterology, 2003, 50(54): 2079-2083.
[35]	Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models[J]. Acad Radiol, 1997, 4(4): 275-282.
[36]	El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127.
[37]	Tsochatzis EA, Fatourou E, O'Beirne J, et al. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(12): 3069-3077.
[38]	Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin（first cooperative study）. The Cooperative Study Group for Liver Cancer Treatment of Japan[J]. Cancer Chemother Pharmacol, 1992, 31(Suppl): S1-S6.
[39]	Chang JM, Tzeng WS, Pan HB, et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study[J]. Cancer, 1994, 74(9): 2449-2453.
[40]	Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
[41]	Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 541-551.
[42]	Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma[J]. Br J Cancer, 2013, 108(6): 1252-1259.
[43]	Tak E, Lee S, Lee J, et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells[J]. J Hepatol, 2011, 54(2): 328-339.
[44]	Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients[J]. World J Hepatol, 2015, 7(16): 2009-2019.
[45]	Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response[J]. AJR Am J Roentgenol, 1999, 172(1): 59-64.
[46]	Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation[J]. Abdom Imaging, 1993, 18(4): 352-356.
[47]	Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update[J]. Oncology, 2014, 87(Suppl 1): 22-31.
[48]	Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology（JSH）2010 updated version[J]. Dig Dis, 2011, 29(3): 339-364.
[49]	Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2261-2273.
[50]	Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process[J]. J Hepatol, 2015, 62(4): 855-862.
[51]	Chen L, Ni CF, Chen SX, et al. A modified model for assessment for retreatment with transarterial chemoembolization in Chinese hepatocellular carcinoma patients[J]. J Vasc Interv Radiol, 2016, 27(9): 1288-1297.

Please choose a citation manager

Content to export